The US Food and Drug Administration should add milestone dates in 2024 so pharmaceutical distribution trading partners can ensure an orderly transition to a package-level product tracing system during the post-deadline stabilization period, the Healthcare Distribution Alliance proposed.
Key Takeaways
-
Most trading partners want an orderly transition to the package-level drug product tracing system required under DSCSA, but some would be happy with...
The alliance, which represents pharmaceutical distributors, also called for the FDA to set and communicate additional expectations intended to motivate a subset of trading partners that have interpreted the stabilization...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?